Cxbladder tests identify high-impact and low-impact tumors
“The purpose of [Cxbladder] Resolve is to identify not only those patients who are at higher risk for urothelial or urinary tract cancer, but those that have a high probability of an aggressive cancer, such as high-grade TA, carcinoma in situ, or T1 to T3,” says Jay Raman, MD, FACS.
In this video, Jay Raman, MD, FACS, discusses how the urinary biomarker Cxbladder tests are used to classify the risk of urothelial cancer in patients with hematuria. Raman is a professor and chair of urology at Penn State Health Milton S. Hershey Medical Center, Penn State University, Pennsylvania.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
